Source link : https://www.newshealth.biz/health-news/mek-inhibitor-scores-big-win-in-adults-children-with-neurofibromatosis-type-1/
Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed. Overall, 53 of 114 patients met response criteria, defined as ≥20% reduction in target plexiform neurofibroma (PN) volume on consecutive MRI scans. Responses occurred in 24 of 58 […]
Author : News Health
Publish date : 2024-11-15 19:18:31
Copyright for syndicated content belongs to the linked Source.
Categories